

GRM8 Antibody (C-term) Blocking peptide Synthetic peptide Catalog # BP13777b

Specification

GRM8 Antibody (C-term) Blocking peptide - Product Information

Primary Accession

<u>000222</u>

GRM8 Antibody (C-term) Blocking peptide - Additional Information

Gene ID 2918

Other Names Metabotropic glutamate receptor 8, mGluR8, GRM8, GPRC1H, MGLUR8

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP13777b was selected from the C-term region of GRM8. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

GRM8 Antibody (C-term) Blocking peptide - Protein Information

Name GRM8

Synonyms GPRC1H, MGLUR8

Function

G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.

Cellular Location Cell membrane; Multi-pass membrane protein.

GRM8 Antibody (C-term) Blocking peptide - Protocols



Provided below are standard protocols that you may find useful for product applications.

<u>Blocking Peptides</u>

GRM8 Antibody (C-term) Blocking peptide - Images

GRM8 Antibody (C-term) Blocking peptide - Background

L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic andmetabotropic glutamate receptors. Glutamatergic neurotransmissionis involved in most aspects of normal brain function and can beperturbed in many neuropathologic conditions. The metabotropicglutamate receptors are a family of G protein-coupled receptors, that have been divided into 3 groups on the basis of sequencehomology, putative signal transduction mechanisms, andpharmacologic properties. Group I includes GRM1 and GRM5 and thesereceptors have been shown to activate phospholipase C. Group Ilincludes GRM2 and GRM3 while Group III includes GRM4, GRM6, GRM7and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but differ in their agonistselectivities. Alternatively spliced transcript variants encodingdifferent isoforms have been described for this gene. [provided byRefSeq].

GRM8 Antibody (C-term) Blocking peptide - References

Saus, E., et al. J Psychiatr Res 44(14):971-978(2010)Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Fonseca, F., et al. Mol Diagn Ther 14(3):171-178(2010)Bozaoglu, K., et al. J. Clin. Endocrinol. Metab. 95(5):2476-2485(2010)Joslyn, G., et al. Alcohol. Clin. Exp. Res. 34(5):800-812(2010)